SCT 1000
Alternative Names: 14 valent HPV vaccine; Recombinant 14 valent Human Papillomavirus Vaccine; SCT-1000Latest Information Update: 20 Sep 2023
At a glance
- Originator Sinocelltech
- Class Papillomavirus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Human papillomavirus infections
Most Recent Events
- 13 Aug 2023 Phase-III clinical trials in Human papillomavirus infections (Prevention, In adults) in China (IM) (NCT06041061)
- 19 Oct 2021 Phase-II clinical trials in Human papillomavirus infections (Prevention) in China (IM) (NCT05060484)
- 01 Oct 2021 Sinocelltech plans a phase II trial in Human papillomavirus infections(Prevention, In adults) (IM) (NCT05060484)